PolyPid Ltd.
PYPD Nasdaq Surgical & Medical Instruments & Apparatus Financials FY2018โFY2025
What PolyPid Ltd. does
No business description yet.
- Legal name
- PolyPid Ltd.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 20-F ยท Feb 25, 2026
- Accession ยท CIK
- 0001213900-26-020370
0001611842
Revenue and margins
PolyPid Ltd. had โ of revenue in fiscal 2025.
Net income and earnings per share
From fiscal 2018 to 2025, diluted EPS grew 13.5% a year. Loss periods are shown in red.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cash flow
Free cash flow was โ$28.1M in fiscal 2025, โ of revenue. Cash from operations minus capital spending.
Dividends, buybacks and share count
PolyPid Ltd. returned โ to shareholders in fiscal 2025. The diluted share count rose 176.5%.
Balance sheet
Cash, debt and the ratios that show how comfortably PolyPid Ltd. can carry it.
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $9.8M | $8.6M | $5.3M | $15.6M | $6.4M |
| Debt incl. finance leases | โ | $11.6M | $10.4M | $7.4M | $1.0M |
| Debt / equity | โ | 2.0x | โ | 1.0x | 0.1x |
| Current ratio | 4.3x | 1.7x | 0.8x | 1.3x | 2.0x |
| Quick ratio | 4.3x | 1.7x | 0.8x | 1.3x | 2.0x |
| Total assets | $44.2M | $26.0M | $15.4M | $25.2M | $22.3M |
| Total liabilities | $8.3M | $20.1M | $17.5M | $17.5M | $11.3M |
| Shareholders' equity | $36.0M | $5.8M | โ$2.1M | $7.7M | $11.0M |
| Net debt (โ = net cash) | โ | $3.0M | $5.1M | โ$8.2M | โ$5.4M |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. โPlanโ marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
โ
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8โ9 is strong, 0โ2 weak.
| Test | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|
| Net income is positive | โ | โ | โ | โ | โ | โ | โ | โ |
| Cash from operations is positive | โ | โ | โ | โ | โ | โ | โ | โ |
| Return on assets rose | โ | โ | โ | โ | โ | โ | โ | โ |
| Cash from operations exceeds net income | โ | โ | โ | โ | โ | โ | โ | โ |
| Debt fell relative to assets | โ | โ | โ | โ | โ | โ | โ | โ |
| Current ratio rose | โ | โ | โ | โ | โ | โ | โ | โ |
| Share count didn't rise | โ | โ | โ | โ | โ | โ | โ | โ |
| Gross margin rose | โ | โ | โ | โ | โ | โ | โ | โ |
| Revenue rose relative to assets | โ | โ | โ | โ | โ | โ | โ | โ |
| F-score | โ / 3 | โ / 4 | โ / 6 | โ / 6 | โ / 6 | 1 / 7 | 4 / 7 | 3 / 7 |
| Accruals ratio | โ | 31.0% | โ27.9% | โ17.0% | โ14.9% | โ32.1% | โ34.8% | โ26.5% |
| Altman Z'' | โ | โ8.64 | 20.71 | โ10.92 | โ35.25 | โ61.18 | โ40.55 | โ50.77 |
8 years of figures
Amounts in USD. Hover a ratioโs name for its definition.
| Fiscal year | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Research and development | $12.6M | $14.1M | $17.0M | $30.6M | $28.0M | $16.1M | $22.8M | $23.8M |
| Operating income | โ$18.4M | โ$18.6M | โ$26.3M | โ$43.1M | โ$38.9M | โ$22.9M | โ$28.0M | โ$33.0M |
| Pretax income | โ | โ | $36.9M | โ$42.6M | โ$39.4M | โ$23.8M | โ$29.0M | โ$34.2M |
| Income tax | โ | โ | โ | โ | $0.1M | $0.1M | $0.0M | $0.0M |
| Net income | $5.9M | โ$6.9M | โ$36.9M | โ$42.6M | โ$39.6M | โ$23.9M | โ$29.0M | โ$34.2M |
| Net income to common | โ$0.1M | $13.3M | $42.9M | $42.6M | $39.6M | โ | โ | โ |
| Diluted EPS | $0.86 | $23.69 | $4.48 | $68.27 | $61.09 | $16.93 | $4.91 | $2.09 |
| Diluted shares | 0.00B | 0.00B | 0.01B | 0.00B | 0.00B | 0.00B | 0.01B | 0.02B |
| Cash flow | ||||||||
| Cash from operations | โ$16.7M | โ$17.4M | โ$21.6M | โ$32.4M | โ$34.3M | โ$17.2M | โ$22.0M | โ$27.9M |
| Capital expenditure | $3.1M | $0.9M | $0.8M | $2.7M | $1.8M | $0.2M | $0.1M | $0.2M |
| Free cash flow | โ$19.8M | โ$18.2M | โ$22.4M | โ$35.0M | โ$36.1M | โ$17.4M | โ$22.0M | โ$28.1M |
| Depreciation and amortization | $0.4M | $0.9M | $1.0M | $1.1M | $1.7M | $1.8M | $1.6M | $1.5M |
| Stock-based compensation | $1.0M | $1.0M | $4.6M | $4.8M | $4.3M | $3.4M | $2.8M | $4.9M |
| Balance sheet | ||||||||
| Cash and short-term investments | $7.8M | $3.9M | $4.3M | $9.8M | $8.6M | $5.3M | $15.6M | $6.4M |
| Total debt | โ | โ | โ | โ | $11.6M | $10.4M | $7.4M | $1.0M |
| Current assets | โ | $27.4M | $47.2M | $34.8M | $14.2M | $6.1M | $16.6M | $15.2M |
| Current liabilities | โ | $2.6M | $2.9M | $8.1M | $8.6M | $7.3M | $12.7M | $7.7M |
| Property and equipment, net | โ | $6.1M | $5.9M | $8.8M | $9.2M | $7.6M | $6.1M | $5.1M |
| Total assets | โ | $33.8M | $75.8M | $44.2M | $26.0M | $15.4M | $25.2M | $22.3M |
| Total liabilities | โ | $121M | $3.1M | $8.3M | $20.1M | $17.5M | $17.5M | $11.3M |
| Shareholders' equity | โ$81.7M | โ$87.6M | $72.8M | $36.0M | $5.8M | โ$2.1M | $7.7M | $11.0M |
| Returns | ||||||||
| Return on capital | โ | โ | โ | โ | โ346.2% | โ606.8% | โ | โ468.5% |
| Return on capital employed | โ | โ59.5% | โ36.0% | โ119.3% | โ223.3% | โ282.8% | โ223.5% | โ226.3% |
| Return on equity | โ | โ | โ | โ78.4% | โ189.3% | โ1,278.6% | โ1,038.7% | โ366.3% |
| Return on assets | โ | โ20.5% | โ67.3% | โ71.0% | โ112.7% | โ115.4% | โ143.0% | โ143.8% |
| Return on tangible equity | โ | โ | 59.0% | 118.5% | 678.6% | โ | โ377.7% | โ311.4% |
| Growth | ||||||||
| Net income growth | โ | โ216.7% | โ | โ | โ | โ | โ | โ |
| EPS growth | โ | 2,654.7% | โ81.1% | 1,423.9% | โ10.5% | โ72.3% | โ71.0% | โ57.4% |
| Share count change | โ | โ8.3% | 1,603.5% | โ93.5% | 3.8% | 119.5% | 316.0% | 176.5% |
| Financial health | ||||||||
| Debt / equity | โ | โ | โ | โ | 2.0x | โ | 1.0x | 0.1x |
| Current ratio | โ | 10.6x | 16.4x | 4.3x | 1.7x | 0.8x | 1.3x | 2.0x |
| Quick ratio | โ | 10.6x | 16.4x | 4.3x | 1.7x | 0.8x | 1.3x | 2.0x |
| Quality scores | ||||||||
| Piotroski F-score | โ | โ | โ | โ | โ | 1.0 | 4.0 | 3.0 |
| Altman Z'' | โ | โ8.6 | 20.7 | โ10.9 | โ35.3 | โ61.2 | โ40.6 | โ50.8 |
| Accruals ratio | โ | 31.0% | โ27.9% | โ17.0% | โ14.9% | โ32.1% | โ34.8% | โ26.5% |
Source: SEC EDGAR XBRL filings (CIK 0001611842). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only โ not investment advice. Check the original filings before relying on any figure.
